Exciva is developing a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease dementia.

We have discovered a vast, expanded universe of novel proteins encoded by the human genome. In analyzing these proteins, we elucidate their respective biological functions, refining our understanding of the molecular underpinnings of human biology and disease. Armed with this knowledge, we’re aiming to create breakthrough medicines for a multitude of diseases.

Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases.

March Biosciences is developing advanced cell therapies, targeting complex diseases like cancer and genetic disorders through precision medicine approaches. Their lead asset, MB-105, selectively targets CD5, a widely expressed antigen both in normal and malignant T-cells.

Komo Biosciences enables accelerated development and manufacturing of therapeutics by translating the utility of high-efficiency integrases to high-efficiency therapeutic development and manufacturing processes.

Latus Bio is developing curative medicines for neurological diseases, enabled by unprecedented AAV capsids that unlock new possibilities for patient care.

UnNatural Products creates entirely new drugs by engineering synthetic molecules to mimic nature’s macrocycles. Their platform produces passively permeable, macrocyclic peptides that access and address traditionally undruggable targets.

Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation.